Circular of 2026 second extraordinary general meeting
Filed with HKEX · Stock code 6872 · · 36 pages · English
If you are in any doubt about this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser. If you have sold or transferred all your shares in TenNor Therapeutics (Suzhou) Limited, you should at once hand this circular, together with the enclosed form of pr
TenNor Therapeutics Suzhou Ltd. on 6ix
Earlier from TenNor Therapeutics Suzhou
- 2026 Interim report
- Formulation of the 2026 h share award scheme; and (2) amendments to the articles of association
- Poll results of the annual shareholders' meeting held on Monday, June 29, 2026
Later from TenNor Therapeutics Suzhou
- Notice of 2026 second extraordinary general meeting
- Form of proxy for 2026 second extraordinary general meeting to be held on October 23, 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement completion of enrollment of the first patient in the multi-center Phase IIb clinical trial of rifaquizinone (TNP-2092) administered via intra-articular injection for the treatment of prosthetic joint infection
- Poll results of the 2026 second extraordinary general meeting held on Friday, October 23, 2026 and amendments to the articles of association
Follow TenNor Therapeutics Suzhou into a list and get an email when it puts out news.
Follow TenNor Therapeutics Suzhou